Trials / Conditions / Mismatch Repair Deficiency

Mismatch Repair Deficiency

18 registered clinical trials studyying Mismatch Repair Deficiency — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wi NCT07385846	Jennifer Leddon	Phase 1
Not Yet Recruiting	Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer NCT07369986	Women's Hospital School Of Medicine Zhejiang University	Phase 2
Not Yet Recruiting	PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer NCT06549855	Peking University People's Hospital	N/A
Recruiting	A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369	7 Hills Pharma, LLC	Phase 1 / Phase 2
Recruiting	Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer NCT06215677	Peking Union Medical College Hospital	N/A
Recruiting	Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease NCT07450612	San Raffaele University	—
Terminated	Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860	Molecular Templates, Inc.	Phase 1
Recruiting	Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Aden NCT05729646	Yu jiren	Phase 2
Terminated	Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer NCT04906382	Floor Backes, MD	EARLY_Phase 1
Recruiting	Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers NCT03935893	Udai Kammula	Phase 2
Withdrawn	Anti-PD-1 +/- RT for MSI-H Solid Tumors NCT04001101	University of Colorado, Denver	Phase 2
Completed	The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival NCT04482608	Sun Yat-sen University	—
Completed	Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome NCT05257057	WellSpan Health	—
Active Not Recruiting	QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Im NCT03228667	ImmunityBio, Inc.	Phase 2
Completed	A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077	Incyte Corporation	Phase 1
Recruiting	SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774	Massive Bio, Inc.	—
Completed	APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors NCT03053466	Apollomics (Australia) Pty. Ltd.	Phase 1
Active Not Recruiting	Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C NCT02983578	M.D. Anderson Cancer Center	Phase 2